Category: Adaptimmune

Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies

Shots: Adaptimmune to receive $150M up front, $150M as additional payments over 5yrs., $3B+ as research, development, regulatory & commercial milestones along with royalties across multiple programs Adaptimmune can opt for 50-50 US profit/cost-share for off-the-shelf products. If it elects to opt-in, Adaptimmune will share 50% of profits & losses from US sales & receive […]

Roche dives further into cancer cell therapy with Adaptimmune deal

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big play now, pledging $150 million upfront to an alliance with Adaptimmune Therapeutics. The Swiss drugmaker is backloading the five-year deal with around $3 billion in milestones, as the two companies […]

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors. […]

Health Innovators – Jo Brewer, Adaptimmune

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic research at UK company Adaptimmune which is transforming cancer immunotherapy with affinity enhanced T-cell receptors. Adaptimmune’s SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. […]